For example, EGFR-targeted therapies with TKIs have been extensively explored for GBM with a better outcome, VEGFR, PD-L1, and PI3K/mTOR pathway-targeted therapies may be promising either as monotherapy or in combination therapy. This evidence concerns the gene PIK3CA and glioblastoma.